Neomorph yesterday announced a collaboration and licensing agreement with Novo Nordisk to discover, develop, and commercialize molecular glue degraders. Molecular glue degraders have emerged lately as a very hot field to reach “undruggable” targets through protein degradation.  “By combining Neomorph’s proprietary glue discovery platform with Novo Nordisk’s vast experience in…

With the goal of “drugging the undruggable,” developer of molecular glue degraders Proxygen has announced a multi-year research collaboration and license agreement with Merck & Co (known as MSD  outside North America). In a deal potentially worth up to $2.55 billion. The companies will identify and develop drugs against multiple…

Monte Rosa Therapeutics this week announced a global development and commercialization agreement with Novartis to advance its VAV1 molecular glue degrader (MGD)-based medicines, including MRT-6160. Monte Rosa will receive an up-front payment of $150 million and is eligible for milestone payments. MRT-6160 is currently in an ongoing Phase I, single…

Eisai and Seed Therapeutics yesterday announced a potential $1.5B+ collaboration to discover, develop, and commercialize novel molecular glue degraders for multiple undisclosed neurodegeneration and oncology targets. The deal combines Seed Tx’s focus on preclinical discovery of such targets and Eisai’s expertise in neurodegeneration and cancer. Seed Tx’s molecular glues attack…

Vertex Pharmaceuticals announced a $945 million-plus collaboration with Orum Therapeutics to develop a different kind of conditioning regimen than the chemotherapies that are currently used. Vertex will use Orum’s dual-precision targeted protein degradation (TPD²®) technology platform to discover targeted conditioning agents for use with gene editing therapies. Orum has granted…

Bristol Myers Squibb is acquiring Orum Therapeutics’ ORM-6151 program for $100M upfront and total deal value of $180M. In a twist on antibody-drug conjugates (ADCs), Orum is pioneering Dual-Precision Targeted Protein Degradation (TPD²) and Targeted Protein Stabilization (TPS²). ORM-6151 is a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the…

Effie Tozzo, PhD Effie Tozzo, PhD, is the chief scientific officer of Avilar Therapeutics, a biopharmaceutical company pioneering the discovery and development of extracellular protein degrader therapeutics, a new frontier applying targeted protein degradation as an innovative drug modality for a wide range of diseases. Prior…